Cost effectiveness of interferon-gamma release assay for school-based tuberculosis screening

Molecular Diagnosis and Therapy

Volumn 16, Issue 3, 2012, Pages 181-190

  Kowada, Akiko ^a  

^a Ota City Public Health Office   (Japan)

Author keywords

Adolescents; Cost effectiveness; Interferon gamma; Radiography; Screening; Tuberculin; Tuberculosis

Indexed keywords

BCG VACCINE; ISONIAZID;

ADOLESCENT; ADULT; AGED; ARTICLE; ASSAY; BCG VACCINATION; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEPATITIS; HIGH SCHOOL STUDENT; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LUNG TUBERCULOSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCHOOL; SCREENING TEST; THORAX RADIOGRAPHY; TUBERCULIN TEST; UNIVERSITY STUDENT;

MYCOBACTERIUM BOVIS BCG;

ADOLESCENT; BCG VACCINE; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INTERFERON-GAMMA RELEASE TESTS; MALE; MARKOV CHAINS; MASS SCREENING; QUALITY-ADJUSTED LIFE YEARS; SCHOOLS; TUBERCULIN TEST; TUBERCULOSIS; UNIVERSITIES; YOUNG ADULT;

EID: 84861673602     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/bf03262207     Document Type: Article

References (38)

1. Hennessey K, Schulte J, Cook L, et al. Tuberculin skin test screening practices among US colleges and universities. JAMA 1998; 280: 2008-2012
2. Winje BA, Oftung F, Korsvold GE, et al. School based screening for tuberculosis infection in Norway: Comparison of positive tuberculin skin test with interferon-gamma release assay. BMC Infect Dis 2008; 8: 140
3. Jacobs S, Warman A, Richardson R, et al. The tuberculin skin test is unreliable in school children BCG-vaccinated in infancy and at low risk of tuberculosis infection. Pediatr Infect Dis J 2011; 30 (9): 754-8
4. Takayama N, Sakiyama H, Okabe N, et al. Cumulative national immunization rate ofBCGvaccine in Japan [in Japanese]. J Jpn Med Assoc 2009; 137: 2132-6
5. Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: A metaanalysis. Chest 2010; 137: 952-68
6. Hardy AB, Varma R, Collyns T, et al. Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: The QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries. Thorax 2010; 65 (2): 178-80
7. Kowada A, Takahashi O, Shimbo T, et al. Cost effectiveness of interferongamma release assay for tuberculosis contact screening in Japan. Mol Diagn Ther 2008; 12 (4): 235-51
8. Kowada A. Cost effectiveness of interferon-gamma release assay for tuberculosis screening of rheumatoid arthritis patients prior to initiation of tumor necrosis factor-A antagonist therapy. Mol Diagn Ther 2010; 14 (6): 367-73
9. Talbot EA, Harland D, Wieland-Alter W, et al. Specificity of the tuberculin skin test and the T-SPOT.TB assay among students in a low-tuberculosis incidence setting. J Am Coll Health 2012; 60 (1): 94-6
10. Ministry of Health, Labor and Welfare. Guidelines of the Japanese School Safety and Health Law for students [in Japanese; online]. Available from URL: Http://law.e-gov.go.jp/htmldata/S33/S33F03501000018.html [Accessed 2012 April 14]
11. Mangura BT, Reichman LB. Periodic chest radiography: Unnecessary, expensive, but still pervasive. Lancet 1999; 353 (9149): 319-20
12. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: An update. Ann Intern Med 2008; 149 (3): 177-84
13. Tattevin P, Casalino E, Fleury L, et al. The validity of medical history, classic symptoms, and chest radiographs in predicting pulmonary tuberculosis: Derivation of a pulmonary tuberculosis prediction model. Chest 1999; 115 (5): 1248-1253
14. Cohen R, Muzaffar S, Capellan J, et al. The validity of classic symptoms and chest radiographic configuration in predicting pulmonary tuberculosis. Chest 1996; 109 (2): 420-3
15. Research Institute of Tuberculosis. Tuberculosis surveillance 2009 [in Japanese]. Tokyo: Research Institute of Tuberculosis, 2009 [online]. Available from URL: Http://www.jata.or.jp/rit/ekigaku/ [Accessed 2012 April 14]
16. Statistics Bureau, Ministry of Internal Affairs andCommunications. Life tables, 2009. Tokyo: Statistics Bureau, 2010 [online]. Available from URL: Http://www.mhlw.go.jp/english/database/db-hw/vs02.html [Accessed 2012 April 14]
17. Tuberculosis Surveillance Center, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association. Tuberculosis annual report 2008 - series 5: Case finding [in Japanese]. Kekkaku 2010; 85 (2): 139-42
18. Ohmori M. Probability of having latent tuberculosis infection in Japan [in Japanese]. Tokyo: Research Institute of Tuberculosis, 2009 May [online]. Available from URL: Www.jata.or.jp/rit/ekigaku/index.php/download-file/-/view/ 961/ [Accessed 2012 April 14]
19. Horsburgh Jr. CR. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350 (20): 2060-7
20. World Health Organization. Tuberculosis country profiles [online]. Available from URL: Http://www.who.int/tb/country/data/profiles/en/index.html [Accessed 2012 April 14]
21. Chee CB, KhinMar KW, Gan SH, et al. Tuberculosis treatment effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens. Eur Respir J 2010; 36 (2): 355-61
22. Tuberculosis Research Committee (Ryoken). Relapse rate of tuberculosis treated with standard regimen of chemotherapy [in Japanese]. Kekkaku 2009; 84: 617-25
23. Yoshiyama T. Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings [in Japanese]. Kekkaku 2000; 75 (11): 629-41
24. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60: 555-64
25. Fountain FF, Tolley E, Chrisman CR, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: A 7-year evaluation from a public health tuberculosis clinic. Chest 2005; 128 (1): 116-23
26. Diel R, Nienhaus A, Schaberg T. Cost-effectiveness of isoniazid chemoprevention in close contacts. Eur Respir J 2005; 26 (3): 465-73
27. Igakutsushin-sya.Medical insurance reimbursement table in Japan [in Japanese]. Tokyo: Igakutsushin-sya, 2010
28. Ministry of Health, Labor and Welfare. Basic survey on wage structure in Japan. Tokyo: Ministry of Health, Labor and Welfare, 2007
29. Statistics Bureau, Director-General for Policy Planning (Statistical Standard) & Statistical Research and Training Institute. Japanese consumer price index 2010 [online]. Available from URL: Http://www.stat.go.jp/english/ data/cpi/index.htm [Accessed 2012 April 14]
30. Ministry of Health, Labor and Welfare. Basic survey on wage structure [online]. Available from URL: Http://www.mhlw.go.jp/english/database/db-l/index. html [Accessed 2012 April 14]
31. Tsevat J, Taylor WC, Wong JB, et al. Isoniazid for the tuberculin reactor: Take it or leave it. Am Rev Respir Dis 1988; 137 (1): 215-20
32. Kowada A, Deshpande GA, Takahashi O, et al. Cost effectiveness of interferon-gamma release assay versus chest X-ray for tuberculosis screening of BCG-vaccinated elderly populations. Mol Diagn Ther 2010; 14 (4): 229-36
33. Kowada A, Deshpande GA, Takahashi O, et al. Cost-effectiveness analysis of interferon-g release assays versus chest X-ray for annual tuberculosis screening of healthcare workers. J Hosp Infec 2011; 78 (2): 152-4
34. Kowada A. Cost-effectiveness of interferon-g release assay versus chest X-ray for tuberculosis screening of employees. Am J Infect Control 2011; 39 (10): E67-72
35. Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of mycobacteriumtuberculosis infection in a school tuberculosis outbreak. Lancet 2003; 361 (9364): 1168-73
36. Liebeschuetz S, Bamber S, Ewer K, et al. Diagnosis of tuberculosis in South African children with a T-cell-based assay: A prospective cohort study. Lancet 2004; 364 (9452): 2196-2203
37. Hill PC, Brookes RH, Adetifa IM, et al. Comparison of enzyme-linked immunospot assay and tuberculin skin test in healthy children exposed to Mycobacterium tuberculosis. Pediatrics 2006; 117: 1542-8
38. Linas BP, Wong AY, Freedberg KA, et al. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med 2011; 184 (5): 590-601